This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hochster, H. Articles by Speyer, J. Search for Related Content PubMed PubMed Citation Articles by Hochster, H. Articles by Speyer, J. Social Bookmarking                            What's this?

Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based Chemotherapy

From the Kaplan Cancer Center and New York University Medical Center, New York, and Albert Einstein College of Medicine, Bronx, NY.

Address reprint requests to Howard Hochster, MD, 160 E 32nd St, New York, NY 10016; email howard.hochster{at}med.nyu.edu

PURPOSE: Twenty-one–day topotecan infusion was administered as second-line therapy in patients with previously treated ovarian cancer (based on our prior favorable phase I experience) to determine its activity, time to progression, and pharmacodynamics.

PATIENTS AND METHODS: Ovarian cancer patients with measurable lesions and one prior platinum-containing regimen were eligible. Topotecan 0.4 mg/m²/d 21-day continuous ambulatory intravenous infusion, with appropriate dose modifications for toxicity, was administered every 28 days. Weekly blood levels of topotecan and topoisomerase-1 (topo-1) levels in peripheral-blood mononuclear cells (PBMCs) were determined for pharmacodynamic correlation.

RESULTS: Twenty-four patients were entered onto the study (six cisplatin-refractory, five relapsing within < 6 months and 13 relapsing > 6 months after platinum-based therapy). A total of 128 cycles of topotecan (median, four cycles per patient; range, one to 12 cycles) were administered. The major toxicity was neutropenia (29% grade 3 in all cycles and 4% grade 4). One episode of grade 4 thrombocytopenia (4%) occurred. Fifty-two percent of the patients had anemia that required transfusions. Eight of 23 patients with measurable disease (35%; 95% confidence interval [CI], 15% to 54%) had partial responses (PRs) lasting longer than 1 month. Two of these patients had minor residual computed tomographic changes but had clinical complete remissions that lasted up to 53 weeks while they were not undergoing further therapy. One patient with nonmeasurable disease had a PR (by CA-125 criteria) that lasted 6 months, for an overall response rate of 38% in nine of 24 patients (95% CI, 18% to 57%). The median time to progression was 26 weeks. Pharmacodynamic analysis demonstrated a statistically significant decrease in free PBMC topo-1 level at weeks 2 and 3 of drug administration. There was a strong statistical correlation between the decrease in free topo-1 levels and increasing area under the curve (AUC) for topotecan. This was confirmed in a pharmacodynamic model.

CONCLUSION: Twenty-one–day infusion is a well-tolerated method of administering topotecan. Pharmacodynamic studies demonstrate correlations between (1) the week of infusion and the PBMC topo-1 level, (2) the AUC of topotecan and the decrease in topo-1 levels, and (3) the change in topo-1 level and the neutrophil nadir. The objective response rate of 35% to 38% (95% CI, 15% to 57%) in this small multicenter study is at the upper level for topotecan therapy in previously treated ovarian cancer. Prolonged topotecan administration therefore warrants further investigation in larger, randomized studies comparing this 21-day schedule with the once-daily-for-5-days schedule.

Presented in part at the American Society of Clinical Oncology Meeting, Philadelphia, PA, May 18-21, 1996, and ECCO-8, September 1996.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				I. E.L.M. Kuppens, E. O. Witteveen, R. C. Jewell, S. A. Radema, E. M. Paul, S. G. Mangum, J. H. Beijnen, E. E. Voest, and J. H.M. Schellens A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients Clin. Cancer Res., June 1, 2007; 13(11): 3276 - 3285. [Abstract] [Full Text] [PDF]

				U Seifart, T Fink, C Schade-Brittinger, K Hans, C Mueller, G Koschel, H Schroeder, R Lorenz, J Dethling, and M Wolf Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer Ann. Onc., January 1, 2007; 18(1): 104 - 109. [Abstract] [Full Text] [PDF]

				F. Muggia, R. Kosloff, L. Liebes, and H. Hochster Topotecan Continuous Infusion: CA-125 Responses Including Patients Pretreated with Other Schedules of Topotecan. Oncologist, May 1, 2006; 11(5): 529 - 531. [Full Text] [PDF]

				D. Mirchandani, H. Hochster, A. Hamilton, L. Liebes, H. Yee, J. P. Curtin, S. Lee, J. Sorich, C. Dellenbaugh, and F. M. Muggia Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer Clin. Cancer Res., August 15, 2005; 11(16): 5912 - 5919. [Abstract] [Full Text] [PDF]

				M. De Cesare, G. Pratesi, S. Veneroni, R. Bergottini, and F. Zunino Efficacy of the Novel Camptothecin Gimatecan against Orthotopic and Metastatic Human Tumor Xenograft Models Clin. Cancer Res., November 1, 2004; 10(21): 7357 - 7364. [Abstract] [Full Text] [PDF]

				N. C. Daw, V. M. Santana, L. C. Iacono, W. L. Furman, D. R. Hawkins, P. J. Houghton, J. C. Panetta, A. J. Gajjar, and C. F. Stewart Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors J. Clin. Oncol., March 1, 2004; 22(5): 829 - 837. [Abstract] [Full Text] [PDF]

				H. Hochster, E. R. Plimack, C. D. Runowicz, J. Speyer, R. C. Wallach, J. Sorich, J. Mandeli, S. Wadler, J. Wright, and F. M. Muggia Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group J. Clin. Oncol., January 1, 2004; 22(1): 120 - 126. [Abstract] [Full Text] [PDF]

				S. Wadler, D. E. Levy, S. T. Lincoln, G. S. Soori, J. C. Schink, and G. Goldberg Topotecan Is an Active Agent in the First-Line Treatment of Metastatic or Recurrent Endometrial Carcinoma: Eastern Cooperative Oncology Group Study E3E93 J. Clin. Oncol., June 1, 2003; 21(11): 2110 - 2114. [Abstract] [Full Text] [PDF]

				M. A. Bookman Developmental Chemotherapy and Management of Recurrent Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167. [Abstract] [Full Text] [PDF]

				Y. Xu and M. A. Villalona-Calero Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann. Onc., December 1, 2002; 13(12): 1841 - 1851. [Abstract] [Full Text] [PDF]

				R. Morris and A. Munkarah Alternate Dosing Schedules for Topotecan in the Treatment of Recurrent Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 29 - 35. [Abstract] [Full Text] [PDF]

				R. L. Coleman Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary Oncologist, October 1, 2002; 7(90005): 46 - 55. [Abstract] [Full Text] [PDF]

				A. Hasenburg, D.-C. Fischer, X.-W. Tong, A. Rojas-Martinez, R. H. Kaufman, I. Ramzy, P. Kohlberger, M. Orlowska-Volk, E. Aguilar-Cordova, and D. G. Kieback Adenovirus-Mediated Thymidine Kinase Gene Therapy for Recurrent Ovarian Cancer: Expression of Coxsackie-Adenovirus Receptor and Integrins {alpha}v{beta}3 and {alpha}v{beta}5 Reproductive Sciences, May 1, 2002; 9(3): 174 - 180. [Abstract] [PDF]

				R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]

				S. Guichard, A. Montazeri, E. Chatelut, I. Hennebelle, R. Bugat, and P. Canal Schedule-dependent Activity of Topotecan in OVCAR-3 Ovarian Carcinoma Xenograft: Pharmacokinetic and Pharmacodynamic Evaluation Clin. Cancer Res., October 1, 2001; 7(10): 3222 - 3228. [Abstract] [Full Text] [PDF]

				B. Ng, E. Kramer, L. Liebes, C. Wasserheit, H. Hochster, E. Blank, R. Ceriani, and P. Furmanski Radiosensitization of Tumor-targeted Radioimmunotherapy with Prolonged Topotecan Infusion in Human Breast Cancer Xenografts Cancer Res., April 1, 2001; 61(7): 2996 - 3001. [Abstract] [Full Text]

				C. Huisman, E. F. Smit, G. Giaccone, and P. E. Postmus Second-Line Chemotherapy in Relapsing or Refractory Non-Small-Cell Lung Cancer: A Review J. Clin. Oncol., November 1, 2000; 18(21): 3722 - 3730. [Abstract] [Full Text] [PDF]